Intervention

MCLA-128

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions13

Lead sponsors shown2

Clinical trials

2 shown

Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined CancersNCT05588609 · 2022-11-17

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid TumorNCT04100694

APPROVED_FOR_MARKETING

Common conditions

Breast Cancer1 Cholangiocarcinoma1 Colorectal Cancer1 Head and Neck Cancer1 Metastatic Castration-resistant Prostate Cancer1 Non Small Cell Lung Cancer1 NRG1 Fusion1 NSCLC Harboring NRG1 Fusion1 Pancreatic Cancer1 Prostate Cancer1 Renal Cell Carcinoma1 Solid Tumor, Unspecified, Adult1 Unknown Primary Tumors1

Leading sponsors

Merus B.V.1 Partner Therapeutics, Inc.1

Trial status mix

APPROVED_FOR_MARKETING1

TERMINATED1

Phase mix

PHASE21

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.